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Abstract  Atrial  fibrillation  (AF),  the  most  common  arrhythmia  in  the  adult  population  world-
wide, represents  a  significant  burden  in  terms  of  cardiovascular  mortality  and  morbidity  and  has
repercussions  on  health  economics.  Oral  anticoagulation  (OAC)  is  key  to  stroke  prevention  in  AF
and, in  recent  years,  results  from  landmark  clinical  trials  of  non-vitamin  K  oral  anticoagulants
(NOAC)  have  triggered  a  paradigm  shift  in  thrombocardiology.  Despite  these  advances,  there  is
still a  significant  residual  vascular  risk  associated  with  silent  AF,  bleeding,  premature  sudden
death and  heart  failure.
The  authors  review  AF  epidemiologic  data,  the  importance  of  new  tools  for  early  AF  detection,
the current  role  of  catheter  ablation  for  rhythm  control  in  AF,  the  state-of-the-art  in  periproce-
dural OAC,  the  optimal  management  of  major  bleeding,  the  causes  of  residual  premature  death
and future  strategies  for  improvements  in  AF  prognosis.
© 2020  Sociedade  Portuguesa  de  Cardiologia.  Published  by  Elsevier  España,  S.L.U.  This  is  an
open access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-
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Otimizar  o  prognóstico  na  fibrilhação  auricular:  um  apelo  à  ação  em  Portugal
Resumo  A  arritmia  mais  comum  na  população  adulta  em  todo  o  mundo,  a  fibrilhação  auricular
(FA), contribui  decisivamente  para  a  elevada  mortalidade  e  morbilidade  cardiovascular,  com
repercussões  na  economia  da  saúde.  A  anticoagulação  oral  (ACO)  é  a  chave  para  a  prevenção
do acidente  vascular  cerebral  na  FA.  Nos  últimos  anos,  os  resultados  dos  grandes  ensaios  clínicos
com os  ACO  não  antagonista  da  vitamina  K  mudaram  o  paradigma  na  trombocardiologia.  Apesar
deste avanço,  o  risco  vascular  residual  associado  à  FA  silenciosa,  hemorragia,  morte  súbita
prematura  e  insuficiência  cardíaca  continua  a  ser  significativo.
Os autores  fazem  uma  revisão  dos  dados  epidemiológicos  da  FA,  a  importância  das  novas
ferramentas  para  a  deteção  precoce  da  FA,  o  papel  atual  da  ablação  por  cateter  no  controlo  do
ritmo na  FA,  o  estado  da  arte  na  ACO  periprocedimento,  a  gestão  ideal  de  hemorragias  graves,
as causas  de  morte  prematura  residual  e  estratégias  futuras  para  a  melhoria  do  prognóstico  da
FA.
© 2020  Sociedade  Portuguesa  de  Cardiologia.  Publicado  por  Elsevier  España,  S.L.U.  Este é um




































































ntroduction: Atrial fibrillation, a  public health
oncern
trial  fibrillation  (AF)  is  the  most  common  arrhythmia  in  the
dult  population  worldwide,  associated  with  high  morbid-
ty,  increased  mortality  risk  and  impaired  quality  of  life.1
onsidering  the  aging  population,  the  increase  in  predis-
osing  factors  for  AF,  and  the  improvement  in  healthcare
ith  increased  survival  rates,  AF  is  becoming  a  major  and
rowing  public  health  concern  involving  significant  expendi-
ure  on  health  resources.2
Stroke  is  the  leading  cause  of  acquired  disability  and  the
econd  leading  cause  of  mortality  worldwide.3 In  Portugal,
troke  leads  the  causes  of  mortality  representing  11%  of  all
eaths,  71%  of  which  are  ischemic  in  nature.4,5 Although
he  global  incidence  of  stroke  is  decreasing,  cardioembolic
troke  has  tripled  in  recent  decades  with  underlying  AF  in  at
east  20%  of  cases.6,7 The  key  preventive  therapy  for  stroke
ssociated  with  AF  is  anticoagulation.1
A  decade  after  a  paradigm  shift  in  thrombocardiology,
ith  the  advent  of  non-vitamin  K  or  direct  oral  anticoag-
lants  (NOACs),8 the  present  document  aims  to  reflect  on
uture  strategies  for  stroke  prevention  in  AF  (SPAF),  and  to
urther  optimize  overall  AF  prognosis  in  Portugal.
The  authors  of  the  present  document  are  cardio-
ogists,  neurologists,  internal  medicine  specialists,  and
mmunohematologists,  who  work  in  the  Portuguese  National
ealth  Service  (NHS)  and  private  hospitals  (including  emer-
ency  departments),  and  academic  centers.  The  opinions
xpressed  herein  are  based  on  their  clinical  and  organi-
ational  experience  and  are  supported  by  national  and
nternational  evidence  and  guidelines.  The  authors  under-
ake  a  review  of  AF  epidemiologic  data,  consider  the
mportance  of  new  tools  for  early  AF  detection,  the  cur-
ent  role  of  catheter  ablation  (CA)  for  rhythm  control  inPlease  cite  this  article  in  press  as:  Ferreira  J,  et  al.  Optimizing
Rev  Port  Cardiol.  2020.  https://doi.org/10.1016/j.repc.2020.0
F  and  the  state-of-the-art  periprocedural  oral  anticoagula-
ion  (OAC),  optimal  management  of  major  bleeding,  causes






nternational and national atrial fibrillation
pidemiologic data
he  2010  Global  Burden  of  Disease  (GBD)  study  estimated  a
lobal  age-adjusted  prevalence  of  up  to  33.5  million  patients
ith  AF  in  2010,  representing  approximately  0.5%  of  the
ntire  world  population  and  reaching  2.5--3.5%  of  the  popu-
ation  in  many  countries.2 Prevalence  is  likely  to  have  been
nderestimated,  as  the  GBD  study  did  not  include  silent  AF,
 subclinical  asymptomatic  type  of  AF.  This  study  showed
hat  the  age-adjusted  incidence  rates  of  AF  were  higher  in
eveloped  countries  compared  with  developing  countries,
ith  greater  rates  found  in  older  individuals.2 Data  from  the
ramingham  Heart  Study  showed  that  the  lifetime  risk  for
evelopment  of  AF  in  men  and  women  aged  ≥40  years  is
pproximately  one  in  four.9
In  Europe,  the  estimated  prevalence  of  AF  is  expected
o  increase  from  8.8  million  adults  in  2010  to  approximately
8  million  by  the  year  2060,10 and  the  current  estimated
revalence  of  AF  in  the  general  population  is  about  3.0%.
In  Portugal,  the  FAMA  study,  a  large-scale  cross-sectional
pidemiological  study  conducted  in  2009,  reported  an  AF
revalence  of  2.5%  in  individuals  aged  ≥40  years,  showing
n  increased  prevalence  with  age,  predominantly  in  the  age
roup  ≥70  years.11 The  real  prevalence  of  AF  may  have  been
nderestimated  as  the  frequency  of  paroxysmal  AF  was  not
ccounted  for  in  these  data.  In  2017,  Primo  et  al.  assessed
he  overall  prevalence  of  AF  and  atrial  flutter  in  individuals
40  years  using  24-hour  electrocardiographic  monitoring;
he  prevalence  observed  was  12.4%.12 Similarly,  a  recent
opulation-based  study  in  elderly  Portuguese  subjects,  the
AFIRA  study,  estimated  an  AF  prevelance  of  9.0%.13
AF  has  been  associated  with  an  increased  risk  of  stroke,
eart  failure  (HF),  thromboembolism,  cognitive  decline,
ementia,  and  death.1 Notably,  AF  increases  the  risk  of
14,15 prognosis  in  atrial  fibrillation:  A  call  to  action  in  Portugal.
7.011
schemic  stroke  up  to  five-fold and  overall,  AF-related
trokes  are  more  severe  and  frequently  fatal.16 However,
he  high  efficacy  of  treatment  with  oral  anticoagulation
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Optimizing  prognosis  in  atrial  fibrillation  
AF-related  strokes  largely  preventable,  reducing  their  rela-
tive  risk  by  64%  and  all-cause  mortality  by  26%  compared
with  control  or  placebo.17 In  recent  years,  NOACs  have
been  developed  to  overcome  some  of  the  clinical  limitations
inherent  to  VKA  therapy,  especially  the  need  for  frequent
laboratory  monitoring,  significant  food  and  drug  interactions
and  higher  risk  of  intracranial  bleeding.1 NOACs  (dabiga-
tran  etexilate,  rivaroxaban,  apixaban,  and  edoxaban)  have
shown  to  be  equally  as  or  more  effective  than  VKA  for  SPAF
(supplementary  material).8,18--20 The  use  of  NOACs  reduced
stroke  or  systemic  embolism  by  19%  and  all-cause  mor-
tality  by  10%  in  recent  meta-analyses  that  compared  the
four  NOACs  with  warfarin.21 Moreover,  a  low  incidence  of
ischemic  stroke  and  major  bleeding  was  also  found  in  a
global  registry  of  long-term  treatment  with  dabigatran,  fur-
ther  confirming  the  safety  and  effectiveness  of  NOACs  for
SPAF.22
A  nationwide  cohort  study  performed  in  Taiwan  showed
that,  although  overall  anticoagulation  use  was  suboptimal,
a  lower  risk  of  ischemic  stroke  and  mortality  was  associated
with  increasing  prescription  rates  of  OAC,  thus  supporting
the  introduction  of  NOACs  into  clinical  practice.23 In  Portu-
gal,  the  increased  use  of  NOACs  for  stroke  prevention  in  AF
is  considered  to  be  one  of  the  major  causes  of  the  observed
decline  in  ischemic  stroke  mortality,  according  to  data  from
the  Portuguese  National  Health  Directory  2017.4
Screening and early diagnosis of atrial
fibrillation
Ischemic  strokes  resulting  from  AF  are  common  and  fre-
quently  fatal,  yet,  at  the  same  time,  they  are  largely
preventable  with  OAC  therapy.1 However,  a  relevant  pro-
portion  of  stroke  patients  is  only  diagnosed  with  silent  AF
after  having  suffered  a  stroke,  failing  at  the  primary  preven-
tion  of  the  vascular  event.24 A  recent  meta-analysis  found
that  approximately  a  quarter  of  patients  are  newly  diag-
nosed  with  AF  after  sequential  cardiac  monitoring  following
a  stroke  or  transient  ischemic  attack  (TIA).25 Similarly,  the
Portuguese  SAFIRA  epidemiological  study  found  that  36%  of
the  population  with  AF  was  unaware  of  having  this  condition
and  that  17%  of  them  were  diagnosed  with  paroxysmal  AF.13
The  European  Society  of  Cardiology  (ESC)  Guidelines  for
AF  proposes  the  opportunistic  screening  of  arrhythmia  by
pulse  check  or  electrocardiogram  (ECG)  strip  in  people  aged
≥65  years,  as  a  class  I  recommendation.1 The  same  class
of  recommendation  is  advocated  for  the  interrogation  of
cardiac  implantable  electronic  devices  and  sub-cutaneous
implantable  cardiac  monitors  (ICMs)  for  detecting  atrial  high
rate  episodes.
The  cause  of  approximately  one  third  of  all  ischemic
strokes  remains  unexplained  after  routine  evaluation,  there-
fore  being  classified,  by  exclusion,  as  cryptogenic.  AF  is
very  often  associated  with  a  stroke  event  initially  labeled
as  cryptogenic.26,27 Two  randomized  trials  have  shown  that
a  prolonged  rhythm  monitoring  strategy  may  be  crucial  to
identify  an  AF  episode  that  would  not  have  been  detectedPlease  cite  this  article  in  press  as:  Ferreira  J,  et  al.  Optimizing
Rev  Port  Cardiol.  2020.  https://doi.org/10.1016/j.repc.2020.0
with  conventional  follow-up  after  a  cryptogenic  stroke  event
(Supplementary  material).28,29 The  EMBRACE  study  found  an
AF  incidence  of  16%  with  a  30-day  ECG  monitoring  strat-







roup  undergoing  24-hr  Holter  monitoring.28 Similarly,  the
RYSTAL-AF  trial  compared  a  six  to  12  month  monitoring
trategy  with  a  subcutaneous  ICM  versus  the  standard  follow-
p  for  detecting  AF.29 AF  was  identified  9%  and  12.4%  of
atients  in  the  ICM  group,  versus  1.4%  and  2.0%  in  the
ontrol  group,  after  six  and  12  months  respectively.29 The
F  episodes  detected  during  the  study  were  most  frequently
symptomatic  and  paroxysmal  (74%  and  79%  at  six  and
2  months  within  the  ICM  group).29 In  patients  with  ischemic
troke  or  TIA,  the  ESC  Guidelines  suggest  screening  for  AF
sing  continuous  ECG  monitoring  for  at  least  72  hours  as
 class  I  recommendation.1 More  prolonged  ECG  monitor-
ng  with  noninvasive  monitors  or  implantable  loop  recorders
hould  be  considered  in  these  patients  to  detect  silent  AF
class  IIa  recommendation).1
We  are  currently  witnessing  a paradigm  shift  in  screening
ools  to  improve  the  early  detection  of  subclinical  AF.30,31
umerous  devices  have  been  developed  based  on  different
echnologies.  Handheld  single-ECG  devices  (e.g.  AliveCor
ardia,  Mydiagnostick)  operating  with  automated  algorithms
ave  demonstrated  a  good  predictive  diagnostic  accuracy
positive  predictive  value  ranging  from  54.8  to  88.9%  and
egative  predictive  value  between  91.1  and  96.1%).32 Auto-
ated  blood  pressure  monitors  (e.g.  Omron  M6,  Microlife
P  A200  Plus)  can  identify  pulse  irregularity  associated  with
F  (positive  predictive  value  81.5  to  83%  and  negative  pre-
ictive  value  98  to  100%).33 Patch  ECG  monitors  (e.g.  Zio
- iRhythm,  Cardiostat  -- Icentia,  Nuvant  - Corventis)  allow
rolonged  rhythm  monitoring  and  were  more  sensitive  than
4-h  Holter  monitoring  for  AF  detection.34 Finally,  photo-
lethysmography  (PPG)  technology  applied  to  mobile  phones
nd  smartwatches  may  play  a  key  role  in  more  widespread
etection  of  AF.  The  Apple  Heart  Study,  which  assessed
he  performance  of  a  smartwatch  PPG-based  algorithm  in
 broad  population  of  over  400  000  participants,  for  the
etection  of  pulse  irregularity  that  might  reveal  previously
nknown  AF,  presented  a  positive  predictive  value  of  71%
Supplementary  material).35 Notably,  an  important  finding
o  overcome  concerns  about  potential  over-notification  is
hat  only  0.5%  of  the  participants  received  an  irregular  pulse
otification.  The  Huawei  Heart  Study  also  demonstrated
he  usefulness  of  PPG-based  technology  in  AF  screening,
ith  a  positive  predictive  value  of  91.6%  (Supplementary
aterial).36 Any  attempt  to  make  indirect  comparisons  on
he  predictive  performance  of  the  various  devices  should
ake  into  account  the  dependence  of  the  predictive  value  of
 test  on  the  prevalence  of  the  disease.37
atheter ablation in atrial fibrillation
A  is  a  well-established  and  effective  treatment  strategy  for
ymptomatic  AF  patients.1 In  fact,  it  is  more  effective  than
ntiarrhythmic  drug  therapy  in  patients  with  symptomatic
aroxysmal,  persistent,  and  probably  long-standing  persis-
ent  AF.38
The  greater  efficacy  of  CA  in  maintaining  sinus  rhythm
as  given  rise  to  the  hypothesis  that  this  therapy  might  be prognosis  in  atrial  fibrillation:  A  call  to  action  in  Portugal.
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uperior  to  a  rate  control  strategy  in  reducing  major  clinical
utcomes,  which  in  patients  under  appropriate  OAC  is  simi-
ar  to  pharmacologic  rhythm  control.39 In  the  CABANA  trial,
















































































































ARTICLEEPC-1632; No. of Pages 11
 
F  requiring  therapy,  CA  was  not  superior  to  pharmaco-
ogic  therapy  in  reducing  the  combined  primary  outcome  of
eath,  disabling  stroke,  serious  bleeding  or  cardiac  arrest
HR  0.86,  CI  95%  0.65  to  1.15)  at  four  years  (Supplementary
aterial).40 However,  CA  significantly  reduced  the  relative
isks  of  the  secondary  endpoints  of  death  or  cardiovascular
ospitalization  by  17%  and  recurrent  AF  by  48%.  Moreover,
A  was  superior  to  drug  therapy  in  reducing  the  relative  risks
f  the  primary  endpoint  by  33%  and  all-cause  death  by  40%  in
he  treatment  received  analysis.  However,  several  method-
logical  issues,  such  as  elevated  cross-over  rates  between
reatment  arms,  have  limited  the  generalizability  of  the
ABANA  trial  results.  On  the  other  hand,  the  CASTLE-AF
rial,41 which  randomized  363  patients  with  AF  and  HF  with
educed  ejection  fraction  (HFrEF)  to  CA  or  standard  treat-
ent,  showed  evidence  of  prognostic  benefit  after  three
ears  of  follow-up,  with  CA  significantly  reducing  the  pri-
ary  outcome  of  death  or  hospitalization  for  HF  (HR  0.62,
I  95%  0.43  to  0.87)  (Supplementary  material).  Results  from
he  ongoing  EAST-AFNET  4  Trial  may  help  to  establish  the
ole  of  CA  in  improving  outcomes,  if  applied  early  after  the
nitial  diagnosis  of  AF.42
Although  CA  is  considered  a  relatively  safe  procedure,
here  are  some  rare  but  severe  periprocedural  complications
ssociated  with  the  technique,  with  the  most  serious
dverse  events  being  stroke  and  severe  bleeding.43 To
educe  the  risk  of  thromboembolic  complications,  patients
hould  not  discontinue  OAC  therapy  (uninterrupted  strat-
gy)  before  CA.1 In  the  COMPARE  trial,  periprocedural  stroke
nd  bleeding  complications  were  significantly  reduced  by
he  uninterrupted  warfarin  strategy  compared  to  bridg-
ng  with  low-molecular-weight  heparin  (Supplementary
aterial).44
The  uninterrupted  anticoagulation  strategy  for  CA  was
lso  assessed  with  NOACs  (Table  1).45--48 The  VENTURE-AF
rial  was  the  first  prospective  randomized  trial  to  com-
are  the  use  of  uninterrupted  rivaroxaban  versus  warfarin
n  patients  undergoing  AF  CA.45 Results  from  this  trial  led
o  the  conclusion  that  the  use  of  uninterrupted  rivarox-
ban  was  feasible  and  that  the  bleeding  event  rates  and
schemic  outcomes  were  low  and  similar  to  those  of  unin-
errupted  warfarin  therapy.  Similar  results  were  observed
ith  other  factor  Xa  (FXa)  inhibitors,  apixaban  in  the  AXAFA-
FNET  5  trial,  and  edoxaban  in  the  ELIMINATE-AF  trial,  when
ompared  with  uninterrupted  warfarin  (Table  1).  In  the  RE-
IRCUIT  trial,  uninterrupted  dabigatran  was  associated  with
ewer  bleeding  complications  than  uninterrupted  warfarin,
orresponding  to  a  significant  absolute  risk  reduction  of
.3%  and  a  relative  risk  reduction  (RRR)  of  77%  in  major
leeding.46
In  the  RE-CIRCUIT  trial,  patients  receiving  dabigatran
equired  a  similar  amount  of  heparin  as  those  under  warfarin
o  achieve  the  target  activated  clotting  time  (ACT)  dur-
ng  ablation,  whereas  patients  treated  with  FXa  inhibitors
equired  approximately  25%  more  heparin  than  those  allo-
ated  to  warfarin.45,48,49 This  difference  may  be  attributed
o  the  distinct  pharmacodynamic  effects  on  the  detection
r  non-detection  of  the  anticoagulant  effect  by  ACT,  forPlease  cite  this  article  in  press  as:  Ferreira  J,  et  al.  Optimizing
Rev  Port  Cardiol.  2020.  https://doi.org/10.1016/j.repc.2020.0
he  thrombin  inhibitor  dabigatran  and  for  the  FXa  inhibitors,
espectively.49
Although  the  previous  results  are  relevant  to  clinical
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elected  young  populations.50 Considering  this,  Yanagisawa
t  al.  conducted  a  retrospective  study  to  specifically  assess
he  efficacy  and  safety  of  uninterrupted  NOAC  use  in  elderly
atients  undergoing  CA  in  AF.51 In  this  study,  the  elderly
roup  (age  ≥75  years)  had  a  significantly  higher  number
f  periprocedural  bleeding  events  when  compared  to  the
ounger  group,  but  no  statistically  significant  differences
ere  found  between  the  patients  taking  NOAC  or  warfarin
n  both  subgroups.  Even  if  these  results  are  not  completely
nexpected,  they  underscore  age  as  an  important  risk  factor
or  bleeding  and  the  need  to  monitor  these  patients  more
losely  during  the  periprocedural  period.
Overall,  findings  from  the  previous  clinical  trials
upport  the  idea  of  using  uninterrupted  NOAC  dur-
ng  CA  in  AF,  which  corroborates  the  latest  2017
RS/EHRA/ECAS/APHRS/SOLAECE  expert  consensus  state-
ent  on  catheter  and  surgical  ablation  of  AF.52
ral anticoagulation optimization to fit patient
rofile
nowledge  of  patient  history  and  clinical  characteristics  is
ssential  to  optimize  OAC  therapy  and  reduce  AF-related-
isks,  complications  and  mortality.53
Several  stroke  risk  stratification  scores  in  AF  patients
ave  been  developed  to  estimate  the  risk  of  thromboem-
olism  to  support  the  decision  to  initiate  OAC.54--56 The
HA2DS2-VASc  score  is  one  of  the  most  referenced  stroke  risk
tratification  scores  in  international  guidelines  concerning
ntithrombotic  prophylaxis  in  AF.55,56 This  score  integrates
nown  stroke  risk  factors,  such  as  age  (≥75  and  65  to
4  years),  congestive  HF  (signs/symptoms  of  HF  or  reduced
eft  ventricular  ejection  fraction),  hypertension  (blood
ressure  >140/90  mmHg  on  at  least  two  occasions  or  cur-
ent  antihypertensive  treatment),  diabetes  (fasting  glucose
126  mg/dL  or  treatment  with  oral  hypoglycemic  agent
nd/or  insulin),  prior  stroke,  TIA  or  thromboembolism,  vas-
ular  disease  (previous  myocardial  infarction,  peripheral
rterial  disease  or  aortic  plaque)  and  female  individuals.55
Other  risk  markers,  such  as  impaired  renal  function,  cer-
ain  biomarkers  and  left  atrial  enlargement  can  improve  risk
tratification  but  the  gain  in  predictive  value  does  not  com-
ensate  the  complexity  of  the  scores  that  include  them.57--59
owever,  they  can  be  useful  in  specific  patients  for  risk
tratification.
The  benefit  of  OAC  in  patients  presenting  a  CHA2DS2-VASc
isk  score  ≥2  in  men  and  ≥3  in  women,  is  strongly  supported
y  clinical  evidence.1,60 On  the  other  hand,  in  intermediate-
isk  patients  (CHA2DS2-VASc  score  1  in  men  and  2  in  women)
he  evidence  is  not  as  robust  and  the  therapeutic  strategies
till  pose  challenges  in  clinical  practice,  with  the  need  to
eigh  up  the  individual  benefit  of  reducing  thromboembolic
isk  and  the  risk  of  bleeding  --  the  concept  of  net  clinical
enefit.1,60--62 Based  on  data  from  the  large  phase  III  trials
f  NOACs,  the  ESC  Working  Group  on  Cardiovascular  Phar-
acotherapy  and  the  ESC  Council  on  Stroke  state  that  in
atients  with  a  single  stroke  risk  factor,  NOAC  with  a  supe- prognosis  in  atrial  fibrillation:  A  call  to  action  in  Portugal.
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ior  net-clinical  benefit  should  be  preferred  over  vitamin  K
ntagonists  (VKAs).61
Concurrently,  patient  bleeding  risk  should  also  be
ssessed  when  defining  the  therapeutic  strategy  and  as  part
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Table  1  Randomized  trials  comparing  uninterrupted  strategies  of  non-vitamin  K  oral  anticoagulant  versus  warfarin  in  patients
undergoing  catheter  ablation  for  atrial  fibrillation.
Study  AXAFA  --  AFNET  547 RE-CIRCUIT46 ELIMINATE-AF48 VENTURE-AF45
Uninterrupted
NOAC
Apixaban  Dabigatran  Edoxaban  Rivaroxaban
Population 633  635  632  248
Mean age
(years)
64** 59.2  59.5  59.6
CHA2DS2-VASc  2.4  2.1  NR  1.6
Ischemic stroke
or  TIA*
0.6%  vs.  0%  0%  vs.  0.3%  0.3%  vs.  0%  0%  vs.  0.8%  (NS)
Major Bleeding*
(HR;  CI  95%  CI)
3.1%  vs.  4.4%  (NS)  1.6%  vs.  6.9%
(0.22;  0.08-0.59)
2.5%  vs.  1.5%  (NS)  0%  vs.  0.4%  (NS)
Total unit  of
heparin  units*
NR  12  402  vs.  11910
(NS)
14  261  vs.  11  473
(p<0.0001)
13  871  vs.  10  964
(p<0.001)
Median TTR  in
warfarin  group
84%  66%  65%  NR































CI: confidence interval; HR: hazard ratio; NOAC: non-vitamin K or
ischemic attack; TTR: time in target range.
of  clinical  practice  management.56 The  HAS-BLED  score  is
the  most  commonly  used  in  AF  patients,  and  has  been  val-
idated  in  patients  on  aspirin,  OAC  (VKA  or  NOAC)  and  no
antithrombotic  therapy,  with  a  high  predictive  value  for
hemorrhagic  events,  especially  intracranial  hemorrhage,  in
different  situations.56,63 Since  it  also  relies  upon  modifiable
bleeding  risk  factors  (uncontrolled  hypertension,  excessive
alcohol  consumption  or  concomitant  use  of  other  drugs  that
may  influence  the  bleeding  risk),  and  the  stroke  risk  usually
outweighs  the  high  bleeding  risk,  a  high  HAS-BLED  score  of
≥3  generally  is  not  a  reason  to  avoid  or  discontinue  anti-
coagulation;  instead,  it  indicates  that  the  patient  should
have  regular  reviews  of  potential  causes  of  bleeding  and
efforts  to  reduce  the  modifiable  bleeding  risk  factors  should
be  made.1,53,56
Another  factor  that  must  be  considered  for  treatment
optimization  is  the  patient’s  ability  to  comply  with  treat-
ment.  Success  in  VKA  treatment  depends  on  anticoagulation
quality  control;  on  the  other  hand,  patients  with  poor
compliance  will  not  benefit  from  NOACS.  They  have  a  short
half-life,  therefore  missing  a  few  doses  will  ultimately  lead
to  sub-therapeutic  drug  concentrations.64 In  both  situations,
if  proper  treatment  adherence  is  not  achieved,  a  higher  risk
of  stroke  and  mortality  is  observed.65--67
There  are  other  important  factors  in  OAC  choice  that
highlight  the  need  to  assess  whether  dose  reductions  or
switch  are  required,  such  as  advanced  age,  abnormally  low
weight,  renal  insufficiency,  specific  bleeding  risk  (e.g.  gas-
trointestinal)  and  drug  interactions.53,64,68,69 The  absence
of  these  risks  should  also  be  considered,  as  in  the  case  of
patients  under  the  age  of  75  years,  in  which  dabigatran
150  mg  significantly  reduced  the  relative  risks  of
stroke/systemic  embolism  (SE),  major  bleeding  and  all-Please  cite  this  article  in  press  as:  Ferreira  J,  et  al.  Optimizing
Rev  Port  Cardiol.  2020.  https://doi.org/10.1016/j.repc.2020.0
cause  death  by  37%,  30%  and  23%  versus  warfarin,
respectively,  or  patients  with  normal  renal  function  (CrCl>80
ml/min)  in  which  the  risk  of  stroke/SE  was  higher  in  patients




ticoagulant; NR: not reported; NS: non-significant; TIA: transient
The  existing  evidence  from  clinical  trials  and  large
bservational  studies  in  different  settings  and  populations,
f  different  available  therapeutic  options,  allows  for  the
hoice  and  management  of  the  best  OAC  to  fit  patients’
haracteristics  (Table  2).
anagement of major bleeding
nticoagulant  are  associated  with  increased  risk  of  bleeding,
enerally  induced  by  traumatic,  inflammatory  or  neoplas-
ic  vascular  injury.  In  the  GARFIELD--AF  study,  enrolling  28
28  patients  with  AF  and  63%  under  OAC,  the  rate  of  first
ccurrence  of  clinically  relevant  bleeding  in  patients  with
r  without  OAC  was  3.0%,  with  a  fatal  outcome  in  6.9%  of
he  events  over  two  year  follow-up.72 Subjects  on  OAC  were
3%  more  likely  to  experience  clinically  relevant  bleeding.
ndeed,  bleeding  was  associated  with  higher  mortality,  rep-
esenting  6%  of  the  causes  of  death  in  patients  with  AF  on
AC,73 and  was  even  more  problematic  in  the  presence  of
ultiple  morbidities,  high  risk  medications,  polypharmacy,
r  drug-drug  interactions.74 Notwithstanding  these  factors,
he  net  clinical  benefit  of  contemporary  OAC  versus  no  treat-
ent  was  overwhelming,  avoiding  50  strokes  and  30  deaths,
t  the  cost  of  two  intracranial  and  one  fatal  bleeding  event
er  1000  patients  treated  over  one  year.75
In  clinical  trials,  NOACs  reduced  the  relative  risks  of
leeding  by  14%  for  major,  52%  for  intracranial  and  47%
or  fatal  events  compared  with  warfarin.21,76 Despite  their
ncreased  safety,  the  use  of  NOACs  is  generally  associated
ith  increased  risk  of  gastrointestinal  bleeding21 and  a  fatal
utcome  is  present  in  9  to  20%  of  patients  who  suffer  a  major
leeding  event.77--79 In  this  setting,  adherence  to  recom- prognosis  in  atrial  fibrillation:  A  call  to  action  in  Portugal.
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ended  management  of  bleeding  guidelines  is  mandatory
Table  3).1,64
The  2016  ESC  Guidelines  for  AF  state  that  the  first
tep  in  the  management  of  patients  with  active  bleeding
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Table  2  Choosing  a  specific  oral  anticoagulant  and  dose  for  stroke  prevention  in  atrial  fibrillation  in  patient  subsets.
Patient  subset  First  choice
Nonvalvular  AF,  paroxysmal,  persistent  or  permanent,
with  a  CHA2DS2-VASc  risk  score  ≥2  in  men  and  ≥3  in
women
OAC  is  recommended  and  NOACs  are  preferred  over
VKAs
Nonvalvular  AF  on  VKA  with  TTR  >70% Continue  with  VKA;  consider  NOAC  if  complication;
SAMe-TT2R2 score  >2;  patients  preference
CHA2DS2-VASc  1  in  men  and  2  in  women  OAC  should  be  considered
Dabigatran  (150  mg  twice  daily  is  preferred)  or  apixaban
may  be  considered
Stable coronary  artery  disease  or  peripheral  artery
disease
Monotherapy  with  a  NOAC
Mechanical  prosthetic  heart  valves  or  moderate/severe
(rheumatic)  mitral  stenosis
VKA
NOACs  should  not  be  used
Secondary  stroke  prevention  NOACs  as  a  group  are  superior  to  warfarin
High risk  of  gastrointestinal  bleeding  Apixaban  5  mg  twice  daily  or  dabigatran  110  mg  twice
daily  may  be  used
Renal impairment  CrCl  30--49  mL/min:  Apixaban  5  mg  twice  daily
(apixaban  2.5  mg  twice  a  day  if  ≥1  additional  criteria:
age ≥80  years,  body  weight  ≤60  kg,  serum  creatinine
≥1.5  mg/dL  are  present),  rivaroxaban  15  mg  daily,
edoxaban  30  mg  once  daily  or  dabigatran  110  mg  twice
daily
Elderly ≥75  years,  we  suggest  apixaban  5  mg  twice  daily  [2.5
mg if  ≥2  of  the  following:  age  ≥80  years,  body  weight
≤60 kg,  or  creatinine  ≥1.5  mg/dL]
Age <75  years  with  preserved  renal  function  Dabigatran  150  mg  twice  daily  may  be  considered
AF: atrial fibrillation; CrCl: creatinine clearance; NOAC: non-vitamin K oral anticoagulant; OAC: oral anticoagulant; VKA: Vitamin K
antagonist.
Table  3  Management  of  active  bleeding  in  patients  on  oral  anticoagulation.9,73
White
•  Identify  the  bleeding  site  and  apply  local  hemostatic  measures
• Obtain  history  of  OAC  (type  and  last  dose)  --  delay  next  OAC  dose
• Assess  hemodynamic  (blood  pressure)  and  laboratorial  (basic  coagulation,  blood  count  and  kidney  function  parameters)  status
Light gray
•  Add  symptomatic  treatment  --  fluid  replacement  and  blood  transfusion
• Treat  bleeding  cause  (e.g.  endoscopy  or  surgery)
Gray
• Consider  specific  reversal  agent  (e.g.  idarucizumab  for  dabigatran  and  andexanet  alfa  for  FXa  inhibitors)























OAC: oral anticoagulant; PCC: prothrombin complex concentrates
White: Minor/Moderate/Severe; Light gray: Moderate/Severe; Gra
s  the  application  of  local  hemostatic  measures  by  means
f  mechanical  compression.1 However,  this  is  not  sufficient
r  even  possible  in  several  bleeding  scenarios.  In  hemor-
hages  occurring  in  deep  organs,  this  therapeutic  approach  is
nly  possible  using  invasive  endoscopic  or  surgical  methods,
hich  is  not  feasible  in  the  context  of  systemic  anticoagu-
ation.
Also,  in  hemorrhages  at  critical  sites  or  associated  with
emodynamic  instability,  reversal  of  OAC  is  mandatory,  toPlease  cite  this  article  in  press  as:  Ferreira  J,  et  al.  Optimizing
Rev  Port  Cardiol.  2020.  https://doi.org/10.1016/j.repc.2020.0
mprove  hemostasis.  For  this  purpose,  reversal  of  OAC  is  also
ritical,  to  allow  spontaneous  hemostasis.64
The  reversal  of  VKAs  includes  the  administration  of  vita-






rozen  plasma  (if  PCC  unavailable).80 Vitamin  K  administra-
ion  is  intravenous,  leading  to  a sustained  but  not  immediate
orrection  of  coagulopathy.  For  patients  with  major  bleed-
ng,  in  order  to  achieve  a  rapid  correction,  PCC  should
e  concomitantly  administrated,  according  to  international
ormalized  ratio  (INR)  and  weight  of  the  patient  (PCC  --  25
/kg  for  INR  2-4;  35  U/kg  for  INR  4-6  and  50  U/kg  if  INR>6).76
hen  PCC  is  not  available,  fresh  frozen  plasma  is  used
10-15  mL/kg);  however,  it  presents  several  disadvantages prognosis  in  atrial  fibrillation:  A  call  to  action  in  Portugal.
7.011
e.g.  it  requires  ABO  blood  typing  and  thawing,  it  has  lower
oncentration  of  coagulation  factors  and  higher  volumes  are
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Idarucizumab  is  approved  as  the  specific  reversal  agent
for  dabigatran.  It  is  an  antigen-binding  fragment  of  a
humanized  monoclonal  antibody  with  a  binding  affinity
approximately  350-fold  more  potent  than  dabigatran’s  affin-
ity  for  thrombin.1,64,81 In  the  RE-VERSE  AD  trial,  an  open
label  and  single-arm  study  that  enrolled  503  patients  with
uncontrolled  bleeding  or  undergoing  an  urgent  procedure,
idarucizumab  (2×2.5  g  intravenous)  rapidly,  durably  and
safely  reversed  the  anticoagulant  effect  of  dabigatran  (Sup-
plementary  material).81 If  unavailable,  PCC  (25-50  U/kg)  can
be  used  as  an  alternative.80
Andexanet  alfa  is  a  modified  recombinant  inactive  form
of  human  factor  Xa  that  binds  FXa  inhibitors  with  an  affinity
similar  to  that  of  native  FXa.  It  was  recently  approved  as  a
specific  reversal  agent  for  the  FXa  inhibitors  apixaban  and
rivaroxaban.  The  ANNEXA-Atrial,  an  open  label  and  single-
arm  study,  enrolled  352  patients  with  acute  major  bleeding
(Supplementary  material).82 This  trial  demonstrated  that
andexanet  alfa  reduced  anti-FXa  activity  substantially.  This
agent  is  administered  as  a  bolus  (400  mg  for  apixaban
or  rivaroxaban  >7  h;  800  mg  for  enoxaparin,  edoxaban  or
rivaroxaban  <7  h)  followed  by  a  two-hour  infusion  (480  mg
for  apixaban  or  rivaroxaban  >7  h;  960  mg  for  enoxaparin,
edoxaban  or  rivaroxaban  <7  h).  For  FXa  inhibitors  under-
evaluated  in  the  ANNEXA-4,  namely  edoxaban,  a  coagulation
factor  supplementation  with  PCCs  is  recommended,  as  well
as  for  the  other  agents  in  the  absence  of  andexanet  alfa.80
The  reversal  agent  ciraparantag,  reported  to  bind  all  the
NOACs,  is  undergoing  phase  III  assessment.80
Reversal  of  the  anticoagulation  effect  with  specific
agents  may  improve  survival  in  patients  with  life-
threatening  bleeds.  Indeed,  although  the  RE-VERSE  AD  and
ANNEXA-4  trials  did  not  include  a  control  group,  30-day
mortality  for  intracranial  hemorrhage  (ICH)  was  16.4%  in
patients  managed  with  idarucizumab  and  21.6%  in  those
managed  with  andexanet  alfa.81,82 These  ICH  mortality  rates
are  notably  lower  than  those  observed  in  the  pivotal  SPAF
NOAC  trials  (from  35  to  45%),  independent  of  OAC  with  VKAs
or  NOACs,  where  patients  were  managed  without  the  use  of
specific  reversal  agents.78,81--83
European  Guidelines  recommend  restarting  OAC  after
a  bleeding  event  in  all  eligible  patients  following  assess-
ment  by  a  multidisciplinary  AF  team,  considering  different
OAC  and  stroke  prevention  interventions,  improved  man-
agement  of  factors  that  contributed  to  the  bleeding,  and
stroke  risk.1 It  is  essential  to  treat  the  culprit  vascu-
lar  lesion  before  restarting  OAC  therapy.  The  majority  of
culprit  lesions  can  be  rapidly  identified  during  diagnostic
work-up  of  gastrointestinal  and  urinary  tract  bleeds.84,85
The  role  of  a  multidisciplinary  team,  comprised  of  stroke
physicians/neurologists,  cardiologists,  internal  medicine
specialists,  surgeons,  neuroradiologists,  immunohematolo-
gists  and  nurses  is  essential  to  this  process,  where  not  only
when  starting  but  also  when  re-starting  OAC,  the  communi-
cation  strategies,  sharing  of  knowledge,  trust,  and  mutual
respect  are  crucial  to  patient  education,  compliance  and
treatment  adherence.1,86
In  patients  with  a  contraindication  for  OAC  treatment,Please  cite  this  article  in  press  as:  Ferreira  J,  et  al.  Optimizing
Rev  Port  Cardiol.  2020.  https://doi.org/10.1016/j.repc.2020.0
left  atrial  appendage  (LAA)  occlusion  may  be  considered  for
SPAF.1 Most  of  the  evidence  on  the  benefit  of  LAA  occlusion
in  SPAF  comes  from  the  PROTECT-AF  and  PREVAIL  trials  (Sup-




nder  oral  anticoagulation.73
V:  cardiovascular;  SE:  systemic  embolism.
on-inferior  to  VKA  treatment  for  the  prevention  of  stroke
ith  lower  bleeding  rates.1
urther prognostic optimization in atrial
brillation
espite  the  great  progress  made  in  stroke  prevention,  death
emains  the  most  frequent  major  event  in  patients  with  AF
n  OAC.21 Cardiovascular  causes  account  for  64%  and  vas-
ular  causes  (embolism  and  bleeding)  for  12%  of  all-cause
eaths  (Figure  1).73 Sudden  cardiac  death  (SCD)  and  HF
ccount  for  43%  of  total  mortality.  NOACs  showed  a  sig-
ificant  10%  reduction  in  all-cause  death  when  compared
o  warfarin,  mainly  driven  by  a  significant  reduction  of
0%  in  the  relative  risk  of  fatal  bleeding.73 In  the  RE-LY
rial,  dabigatran  was  associated  with  a  significant  relative
eduction  of  37%  in  vascular  death.89 Optimal  treatment  for
F  defined  by  the  combined  use  of  angiotensin-converting
nzyme  inhibitor  (ACEI)/angiotensin  receptor  blocker  (ARB)
nd  beta-blocker  (BB)  was  associated  with  a  significant  rel-
tive  reduction  of  41%  in  SCD  in  patients  with  HF.89
Another  area  of  particular  interest  in  AF  is  HF;  they
requently  coexist  and  deteriorate  each  other.90--92 The
revalence  of  AF  increases  with  the  severity  of  HF  and  is
 marker  of  disease  progression.  On  the  other  hand,  AF  is
 predictor  of  mortality  in  patients  with  HF  and  HF  is  a
ajor  risk  factor  for  stroke  in  AF.93,94 In  this  setting,  CA  sig-
ificantly  reduced  the  relative  risks  of  all-cause  death  and
ospitalizations  for  HF  by  47%  and  44%,  respectively  in  the
41 prognosis  in  atrial  fibrillation:  A  call  to  action  in  Portugal.
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forementioned  CASTLE-AF  study.
Ablation  was  associated  with  a  lower  risk  of  ischemic
troke  compared  with  medical  therapy  in  a  real-world  popu-
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enefit  from  primary  prevention  and  management  of  the
hared  underlying  risk  factors  with  SCD  and  HF.  Further
nterventions,  beyond  appropriate  anticoagulation,  are  nec-
ssary  to  reduce  the  risk  of  outcomes  other  than  stroke,  in
atients  with  AF.  This  improvement  includes  the  appropri-
te  management  and  treatment  of  relevant  comorbidities
uch  as  diabetes,  hypertension,  obesity,  obstructive  sleep
pnea  and  thyroid  disease,  as  well  as  healthy  lifestyle
hanges96;  abstinence  from  alcohol  significantly  reduced  AF
ecurrence.97 Retrospective  analysis  from  randomized  trials
f  sodium-glucose  cotransporter  2  inhibitors  have  reported
 lower  incidence  of  new-onset  AF  in  patients  with  type  2
iabetes  (T2DM)98 and  significant  reductions  in  CV  death  or
ospitalization  for  HF  in  patients  with  AF,  CV  disease  and
2DM.99 Similarly,  the  use  of  ACEI/ARB,  BB  or  eplerenone
n  patients  with  HFrEF  has  been  associated  with  a lower
ncidence  of  new-onset  AF.1
onclusions & future strategies
pidemiological  data  at  a  global,  European  and  national
evel  reveal  the  pandemic  nature  of  AF  and  some  recent
tudies  point  to  a  reduction  in  stroke  events  with  greater
ccess  to  OAC  via  NOACs.
Considering  that  a  significant  proportion  of  the  total  AF
opulation  is  asymptomatic  or  mildly  symptomatic,  early
etection  in  these  undiagnosed  patients  is  crucial  for  a
imely  start  of  OAC  therapy  in  order  to  avoid  ischemic  stroke
rom  being  the  first  clinical  manifestation  of  AF,  as  well
s  strategies  to  prevent  AF  progression  to  HF  and  other
omplications.  Therefore,  new  technologies  and  tools  aim-
ng  at  screening  and  for  simple,  timely,  and  accurate  AF
etection  will  need  to  be  implemented  in  routine  clinical
ractice.
There  is  increasing  evidence  that  AF  CA  has  a  prognostic
mpact,  particularly  in  some  patients  with  HF  and  severely
educed  ejection  fraction.  However,  to  achieve  the  best
isk-benefit  ratio,  the  procedure  should  be  performed  under
ninterrupted  anticoagulation.
Even  though  antithrombotic  prophylaxis  with  OAC
educes  the  risk  of  ischemic  stroke  in  AF,  major  bleeding
s  the  most  frequent  adverse  reaction,  representing  6%  of
he  causes  of  death  in  patients  with  AF  on  OAC.  Specific
atient  clinical  characteristics  may  influence  the  bleeding
isk.  Therefore,  choosing  the  appropriate  OAC  and  the  right
ose  that  fits  the  patient  profile  better  is  essential  in  order
o  optimize  therapy  and  reduce  the  risk  of  non-fatal  and
atal  hemorrhages  in  AF  patients.
Managing  major  bleeding  in  patients  on  OAC  can  pose
hallenges.  Current  management  focuses  on  the  expedited
earch  for  the  underlying  vascular  injury  and  local  hemosta-
is.  However,  in  the  setting  of  invasive  procedures,  reversal
f  OAC  is  critical  to  undertake  this  therapeutic  approach.
NOACs  reduce  premature  death  in  patients  with  AF,  but  in
he  ideal  scenario  of  widespread  use  of  these  agents,  more
han  40%  of  fatalities  are  due  to  SCD  and  HF.  Therefore,Please  cite  this  article  in  press  as:  Ferreira  J,  et  al.  Optimizing
Rev  Port  Cardiol.  2020.  https://doi.org/10.1016/j.repc.2020.0
atients  with  AF  need  evidence-based  therapeutic  strategies
or  the  prevention  of  HF  and  SCD,  on  the  development  of
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